MAGE-A4 IHC 1F9 pharmDx
Agilent Technologies, Inc. · Decision date Aug 1, 2024
What did the FDA approve?
The FDA database lists an approval decision dated 2024-08-01 for MAGE-A4 IHC 1F9 pharmDx, submitted by Agilent Technologies, Inc. under product code SBL. The supplied record identifies no supplement type or reason, so it does not establish this as a supplement to an earlier PMA; the decision is described only at the level of the device record.
The statement describes a qualitative immunohistochemical assay using monoclonal mouse anti-MAGE-A4, Clone OTI1F9, on the EnVision FLEX visualization system with Autostainer Link 48, for detecting MAGE-A4 protein in formalin-fixed, paraffin-embedded synovial sarcoma tissue. Expression is scored with the MAGE-A4 Tumor Intensity Proportion Score, counting viable tumor cells with nuclear and/or cytoplasmic staining at intensity ? 2+, with a positive specimen at ? 75%. The stated indication is aid in identifying adult synovial sarcoma patients for whom TECELRA (afamitresgene autoleucel) is being considered.
FDA approval order statement
MAGE-A4 IHC 1F9 pharmDx is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-MAGE-A4, Clone OTI1F9, intended for use in the detection of MAGE-A4 protein in formalin-fixed, paraffin-embedded (FFPE) synovial sarcoma tissues using the EnVision FLEX visualization system on Autostainer Link 48. MAGE-A4 protein expression in synovial sarcoma is determined by using the MAGE-A4 Tumor Intensity Proportion Score (TIPS), which is the overall percentage of viable tumor cells showing MAGE-A4 nuclear and/or cytoplasmic staining at staining intensity ? 2+. The specimen should be considered positive if MAGE-A4 TIPS (? 2+) is ? 75%.MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying adult patients with synovial sarcoma for whom TECELRA (afamitresgene autoleucel), a MAGE-A4 directed genetically modified autologous T- cell immunotherapy is being considered.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Aug 1, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230016
- Regulatory pathway
- Premarket approval application
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- Decision code
- APPR
- Decision date
- Aug 1, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230016 received
Application receipt date recorded by FDA.
P230016 · FDA decision
APPR
P230016/S005 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
P230016/S003 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
P230016/S004 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MAGE-A4 IHC 1F9 pharmDxP230016/S005 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S003 | Agilent Technologies, Inc. | PMA supplement | Sep 15, 2026 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S004 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6392 Via Real, Carpinteria, CA, 93013
Sources and methodology
- Original FDA record: P230016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

